Related Experiment Video
Updated: Aug 4, 2026
11:49
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases
L M Gomez1, J-M Anaya, C I Gonzalez
1Cellular Biology and Immunogenetics Unit (CBIU), Corporación para Investigaciones Biológicas (CIB) and Universidad de Antioquia, Medellin, Colombia, CSIC, Granada, Spain.
Genes and Immunity
|September 16, 2005
Summary
The PTPN22 gene's 1858 T allele is a risk factor for primary Sjogren's syndrome, systemic lupus erythematosus, and Type 1 diabetes in Colombians. This confirms PTPN22's role in autoimmune diseases.
Area of Science:
- Immunogenetics
- Human Genetics
- Autoimmunity
Background:
- A functional single nucleotide polymorphism (SNP) C1858T in the protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene is linked to autoimmune diseases in Caucasians.
- SNP frequencies and their associations can vary significantly across different populations.
- Replication studies are crucial for validating genetic associations in diverse ethnic groups.
Purpose of the Study:
- To investigate the influence of the PTPN22 gene polymorphism (C1858T) in a Colombian population.
- To determine if the PTPN22 1858 T allele is associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren's syndrome (pSS), and Type 1 diabetes (T1D).
Main Methods:
- Genotyping of the PTPN22 gene was performed using real-time polymerase chain reaction (PCR) with the Taq Man 5'-allele discrimination assay.
- A cohort of 621 Colombian patients diagnosed with four autoimmune diseases (RA, SLE, pSS, T1D) was studied.
- A control group of 308 healthy individuals was included for comparison.
Main Results:
- The 1858 T allele of the PTPN22 gene was identified as a significant risk factor for pSS (OR=2.42), SLE (OR=2.56), and T1D (OR=1.83).
- A trend towards increased risk was observed for RA (OR=1.26), although it did not reach statistical significance.
- The findings highlight population-specific effects of the PTPN22 polymorphism on autoimmune disease susceptibility.
Conclusions:
- The PTPN22 gene polymorphism is confirmed to play a role in the development of autoimmunity in the studied Colombian population.
- The results suggest that autoimmune diseases may share common immunogenetic mechanisms, with certain genes like PTPN22 contributing to pleiotropic outcomes.
- Further research into population-specific genetic factors is warranted for understanding autoimmune disease etiology.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...